Key facts
- It has raised $1.3M; the latest was Early Stage VC in Dec 2025.
- Notable investors include MassChallenge, Venture Kick, Innosuisse, Kickfund, Swissnex — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for AzureCell Therapies
- ·The full record, as it builds
Funding rounds
No funding rounds for AzureCell Therapies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AzureCell Therapies
Developer of regenerative therapies designed to restore neural function and address neurodegeneration through engineered cell integration. The company offers lab-grown neurons from donor stem cells with controlled production, safety features, and long-term brain compatibility, enabling healthcare providers to deliver consistent treatments for neurological conditions such as Parkinson's disease with reduced risk and improved therapeutic outcomes.
- Sector
- Healthcare
- HQ
- Lausanne, Switzerland
- Founded
- 2024
- Employees
- 4
- Ownership
- Privately Held (backing)
AzureCell Therapies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AzureCell Therapies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AzureCell Therapies in its N-PORT filings yet. We sweep new filings monthly.